in vivo News and Research

RSS

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

PsychoGenics today announced the establishment of an alliance with KineMed, to provide specialized neurogenesis services to complement PsychoGenics' in vivo testing capabilities.

15 Feb 2011

Public-sector research has had an immediate effect on improving public health: Study

AUTM President Ashley Stevens, D. Phil. (Oxon), CLP is the lead author of The Role of Public Sector Research in the Discovery of Drugs and Vaccines, a paper published in the Feb. 10 issue of The New England Journal of Medicine.

14 Feb 2011

Scientists develop novel treatment strategy for multiple myeloma

Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The study's findings, published in today's edition of the journal "Blood," are the first to demonstrate the synergistic, anti-myeloma effects of this combination regimen both in vitro and in vivo.

11 Feb 2011

Evotec signs definitive agreement to acquire all shares in Kinaxo

Evotec AG today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs.

9 Feb 2011

Eviagenics closes financing round for EUR 1.3 million to commercialize its technology platform

Eviagenics, a French biotech company, is pleased to announce the closing of a series A financing round to scale up its technical and commercial development. At this occasion the FCPR Emertec 4 managed by Emertec Management, CEA Investissement, and Genopole Premier Jour managed by CapDecisif Management provide a total contribution of EUR 1.3 million.

9 Feb 2011

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

PharmaMar SA has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

7 Feb 2011

Human Vaccines journal publishes paper on Inovio's new DNA vaccine delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of electroporation without contacting the skin, is highlighted in a paper published in the scientific journal Human Vaccines.

7 Feb 2011

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

EntreMed, Inc., today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor. The clinical data were published in the December 3, 2010 on-line issue of the American Association for Cancer Research journal, Clinical Cancer Research, and are expected to appear soon in the print version of the publication.

4 Feb 2011

Engineered cells take control of the cells and microenvironment following transplantation

In work that could jumpstart the promising field of cell therapy, in which cells are transplanted into the body to treat a variety of diseases and tissue defects, researchers at Brigham and Women's Hospital (BWH) have engineered cells that could solve one of the key challenges associated with the procedure: control of the cells and their microenvironment following transplantation.

4 Feb 2011

Research unmasks long sought stem cell origin of carcinoma

A constellation of different stem cell populations within our skin help it to cope with normal wear and tear. By constantly proliferating, the stem cells allow skin to replenish itself, allowing each cell to be replaced by a new one about once a month. But the normal cycle of division and death within one or more of these stem cell types can sometimes be derailed by genetic mishaps. Such events are believed to spawn carcinomas and other deadly skin cancers, which are the mostly frequently diagnosed cancers in the United States.

4 Feb 2011

MicroCHIPS commences first hPTH clinical study in women with osteoporosis

MicroCHIPS, a developer of innovative drug delivery systems, is initiating the first clinical study to demonstrate precisely controlled delivery of a peptide from a multi-reservoir, programmable, implant system.

4 Feb 2011

Inspiration presents IB1001 PK data for treatment of hemophilia B

Inspiration Biopharmaceuticals, today presented pharmacokinetic data on its lead product, IB1001, a recombinant factor IX for the treatment and prevention of bleeding in individuals with hemophilia B.

3 Feb 2011

Coordinated behavior occurs whether or not neurons are actually connected via synapses

The brain-awake and sleeping-is awash in electrical activity, and not just from the individual pings of single neurons communicating with each other. In fact, the brain is enveloped in countless overlapping electric fields, generated by the neural circuits of scores of communicating neurons.

3 Feb 2011

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Concert Pharmaceuticals, Inc. today announced that it has entered into a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research. The CRADA will allow the WRAIR to conduct preclinical testing on a novel compound derived from Concert's DCE Platform™ (deuterated chemical entity platform) for seizure protection associated with traumatic brain injury, a major public health concern.

3 Feb 2011

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Aphios® Corporation today announced that it has entered into a subcontract with SAIC-Frederick, a subsidiary of Science Applications International Corporation, to develop phospholipid nanoencapsulated camptothecin, Camposomes™, for the treatment of pancreatic and other cancers, supporting the NCI Alliance for Nanotechnology.

2 Feb 2011

Bioengineers and physician-scientists zap tumors with light-activated nanoparticles

Rice University bioengineers and physician-scientists at Baylor College of Medicine and Texas Children's Hospital have successfully destroyed tumors of human brain cancer cells in the first animal tests of a minimally invasive treatment that zaps glioma tumors with heat. The tests involved nanoshells, light-activated nanoparticles that are designed to destroy tumors with heat and avoid the unwanted side effects of drug and radiation therapies.

2 Feb 2011

Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

Antares Pharma, Inc. today announced that the first patient has been dosed in a clinical study evaluating the VIBEX™ MTX product which is being developed for the treatment of rheumatoid arthritis. The clinical study will evaluate several dose strengths of VIBEX MTX delivered with a proprietary autoinjector versus conventional needle and syringe administration by a healthcare professional.

2 Feb 2011

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

Positron emission tomography can image metabolic changes following treatment with the protein kinase inhibitor vandetanib, helping to define the therapy response or the effectiveness of the therapeutic agent, according to research published in the February issue of The Journal of Nuclear Medicine.

1 Feb 2011

Research shows nestin regulates formation of neuromuscular junction

In a study published in the Jan. 30, 2011, advance online edition of Nature Neuroscience, Salk Institute of Biological Studies investigators led by Kuo-Fen Lee, PhD., show that nestin has reason for being in a completely different cell type--muscle tissue.

30 Jan 2011

Scientists use full genome sequencing to identify precise steps in molecular evolution of S. pneumoniae

Despite penicillin and the dozens of antibiotics that followed it, streptococcus bacteria have remained a major threat to health throughout the world. The reason: the superb evolutionary skills of this pathogen to rapidly alter its genetic makeup.

29 Jan 2011

in vivo News and Research

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

Public-sector research has had an immediate effect on improving public health: Study

Scientists develop novel treatment strategy for multiple myeloma

Evotec signs definitive agreement to acquire all shares in Kinaxo

Eviagenics closes financing round for EUR 1.3 million to commercialize its technology platform

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

Human Vaccines journal publishes paper on Inovio's new DNA vaccine delivery technology

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

Engineered cells take control of the cells and microenvironment following transplantation

Research unmasks long sought stem cell origin of carcinoma

MicroCHIPS commences first hPTH clinical study in women with osteoporosis

Inspiration presents IB1001 PK data for treatment of hemophilia B

Coordinated behavior occurs whether or not neurons are actually connected via synapses

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Bioengineers and physician-scientists zap tumors with light-activated nanoparticles

Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

Research shows nestin regulates formation of neuromuscular junction

Scientists use full genome sequencing to identify precise steps in molecular evolution of S. pneumoniae

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News